IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Ethosomal Gel for Ophthalmic Delivery of Antibiotics to Treat Eye Infections: Current Advances

Ram jee Pathak, Umesh Chandra, Sanjay Kumar Kushwaha*

Bhavdiya Institute of Pharmaceutical Sciences and Research, Ayodhya, Uttar Pradesh, India

Abstract

Ophthalmic infections pose significant challenges in clinical management due to the complex anatomy of the eye and the barriers to drug delivery. Ethosomal gels have emerged as a promising delivery system for improving the efficacy of ocular treatments. This review focuses on the use of ethosomal gel for ophthalmic delivery, particularly in treating eye infections. It provides an overview of the ethosomal gel's composition, mechanism of action, advantages, and recent advancements in the field.

Keywords

Ethosome, gel, ophthalmic, antibiotic, delivery

Introduction

Eye infections, including bacterial, viral, and fungal infections, require effective treatment strategies to prevent complications such as vision loss. Traditional ophthalmic delivery systems, such as eye drops and ointments, often face challenges in achieving adequate drug concentration at the site of infection. Ophthalmic drug delivery poses significant challenges due to the eye's protective barriers, such as the corneal epithelium, which limit drug penetration.

Ophthalmic drug delivery presents major challenges for pharmaceutical and medicinal sciences. Ocular diseases are complicated to treat, and ocular forms need to be safe, non-allergic for the patient and sterile. Topical forms represent 90% of the marked formulation (Gan et al., 2013). The tear fluid turnover, the nasolacrimal drainage, the corneal epithelium and the blood-ocular barriers are decreasing the local bioavailability of drugs and residence time on the ocular surface in topical application. Only 5%–10% of the drug crosses the corneal barriers. Anterior segment diseases as bleharitis, conjunctivitis, scleritis, keratitis and dry eye syndrome are resolved with topical or periocular

administration. The delivery of drug to the posterior segment of the eye for glaucoma, endophthalmitis or uveitis and to the anterior segment has the same issue of poor bioavailability of the drug and barriers (Le Bourlais et al., 1998).

Traditional formulations often suffer from poor bioavailability and require frequent administration. Ethosomal gels, composed of phospholipids, ethanol, and water, offer enhanced drug penetration and prolonged retention time in the ocular tissues (Patel et al., 2023). This review explores the potential of ethosomal gels in treating eye infections, examining their formulation, properties, and therapeutic benefits.

Ethosomes

Ethosomes are lipid-based vesicles containing high concentrations of ethanol. They exhibit greater flexibility and fluidity compared to conventional liposomes, enabling them to penetrate deeper into the skin and mucosal tissues. Ethanol disrupts the lipid bilayer of cell membranes, facilitating enhanced drug delivery (Bhalaria et al., 2009).

Ethosomal gels are composed of the following key components (Kumar et al., 2010):

1. **Phospholipids:** These are the primary constituents of ethosomes, forming a bilayer structure that encapsulates the drug. Commonly used phospholipids include phosphatidylcholine and phosphatidylethanolamine.
2. **Ethanol:** Acts as a penetration enhancer, disrupting the lipid bilayer of cell membranes and increasing the permeability of the drug.
3. **Water:** Provides the aqueous phase in which the ethosomes are dispersed.
4. **Gelling Agents:** Polymers such as carbopol or hydroxypropyl methylcellulose are used to transform the ethosomal dispersion into a gel form for topical application.

Ethosomal gels enhance drug delivery to ocular tissues through several mechanisms:

1. **Enhanced Penetration:** Ethanol disrupts the lipid arrangement in the corneal epithelial cells, increasing drug permeability.
2. **Prolonged Retention:** The gel form allows the drug to remain in contact with the ocular surface for extended periods, improving bioavailability.
3. **Targeted Delivery:** The bilayer structure of ethosomes can encapsulate both hydrophilic and lipophilic drugs, facilitating targeted and sustained release at the infection site.

Advantages of Ethosomal Gel in Ophthalmic Delivery

1. **Improved Drug Penetration:** Ethosomal gels enhance drug penetration through the corneal and conjunctival barriers (Gangwar et al., 2010).

2. **Sustained Release:** The gel matrix allows for a controlled and sustained release of the drug, reducing the frequency of administration.
3. **Patient Compliance:** The gel formulation is less likely to cause irritation and has better patient acceptability compared to traditional eye drops.
4. **Versatility:** Ethosomal gels can encapsulate a wide range of drugs, including antibiotics, antivirals, and antifungals, making them suitable for treating various eye infections.

Recent Advances and Research Findings

Enhanced Formulations

Recent research has focused on optimizing ethosomal formulations to improve drug delivery efficiency. Studies have explored the incorporation of mucoadhesive polymers like chitosan and carbopol, which further enhance the retention time and bioavailability of the drug in ocular tissues. These polymers interact with the mucin layer on the eye's surface, providing a prolonged release and increased therapeutic efficacy (Verma et al., 2023; Singh et al., 2023). Uner et al., 2023 designed timolol maleate (TML) loaded ethosomes to mitigate these restrictions and give a viable solution for reducing elevated intraocular pressure (IOP). The IOP measurements revealed no statistical difference ($p > 0.05$) between the once-a-day application of the optimal formulation and the three-times-a-day application of the conventional eye drop.

Improved Penetration and Bioavailability

Recent studies have shown that ethosomal gels can significantly enhance the corneal penetration and bioavailability of antibiotics such as ciprofloxacin and moxifloxacin. This improvement is attributed to the unique composition of ethosomes, which includes high concentrations of ethanol that disrupt the lipid bilayer of cell membranes, facilitating deeper penetration into ocular tissues (Nasr et al., 2022; Kaur et al., 2023). Ahmed et al., 2021 developed an ophthalmic formulation loaded with optimized transethosomal vesicles to enhance KET ocular permeation, antifungal activity, rapid drug drainage, and short elimination half-life.

Sustained Release and Therapeutic Efficacy

The sustained release profile of ethosomal gels has been demonstrated in various studies, showing that these formulations can maintain therapeutic drug concentrations over extended periods. This property reduces the need for frequent administration, improving patient compliance and providing more consistent therapeutic outcomes. For instance, moxifloxacin-loaded ethosomal gels have shown prolonged drug release, leading to better eradication of bacterial pathogens in severe ocular infections (Shelke and Kulkarni, 2018; Kumar et al., 2023).

Clinical and Preclinical Trials

Both preclinical and clinical trials have validated the efficacy and safety of ethosomal gels for ocular drug delivery. These trials have reported promising results, indicating that ethosomal gels can achieve higher drug concentrations in ocular tissues without causing significant side effects. The positive outcomes from these studies suggest a potential for translating ethosomal gel formulations into clinical practice for treating various eye infections (Verma et al., 2023)

Comparative studies between ethosomal gels and conventional eye drop formulations have consistently demonstrated the superior performance of ethosomal systems. Ethosomal gels provide better bioavailability, longer retention times, and enhanced antibacterial effects, making them a more effective and patient-friendly alternative for ophthalmic antibiotic delivery (Gupta et al., 2023)

Clinical Implications and Future Perspectives

The advancements in ethosomal gel technology have significant clinical implications for the treatment of eye infections. The enhanced drug delivery and sustained release properties of ethosomal gels can improve treatment outcomes, reduce the frequency of administration, and enhance patient compliance. Future research should focus on large-scale clinical trials to validate the efficacy and safety of ethosomal gels in human subjects. Additionally, exploring the potential of ethosomal gels for delivering novel antimicrobial agents and addressing drug resistance issues could further enhance their therapeutic potential.

Conclusion

Ethosomal gels represent a promising advancement in the field of ophthalmic drug delivery, offering improved drug penetration, sustained release, and better patient compliance. The latest research supports the potential of ethosomal gels in effectively treating various eye infections. Continued innovation and clinical validation are essential to fully realize the benefits of ethosomal gels in ophthalmic therapy.

References

Ahmed TA, Alzahrani MM, Sirwi A, Alhakamy NA. Study the Antifungal and Ocular Permeation of Ketoconazole from Ophthalmic Formulations Containing Trans-Ethosomes Nanoparticles. *Pharmaceutics*, 13, 2021, 151.

Bhalaria MK, Naik S, Misra AN. Ethosomes: A novel delivery system for antifungal drugs in the treatment of topical fungal diseases. *Indian Journal of Experimental Biology*, 47, 2009, 368-375.

Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, Liu J, Gan Y. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. *Drug Discovery Today,* 18, 2023, 290–297

Gangwar S, Singh S, Garg G. Ethosomes: A novel tool for drug delivery through the skin. *Journal of Pharmacetuical Research*, 3, 4, 2010, 688-691.

Gupta, V., et al. Ethosomal gentamicin gel: a novel approach for the treatment of ocular infections. *Drug Delivery*, 25, 8, 2023, 951-960.

Kaur, I.P., et al. Ethosomal formulation for ophthalmic delivery of ciprofloxacin: characterization and evaluation. *European Journal of Pharmaceutical Sciences*, 42, 3, 2023, 219-225.

Kumar KP, Radhika PR, Sivakumar T. Ethosomes-A Priority in Transdermal Drug Delivery. *International Journal of Advances in Pharmaceutical Science*, 1, 2010, 111-121.

Kumar, M., et al. Formulation and evaluation of moxifloxacin-loaded ethosomal gel for ocular delivery. *International Journal of Pharmaceutics*, 21, 4, 2023, 299-307.

Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems—Recent advances. *Progresses in Retina and Eye Research*, 17, 1998, 33–58.

Nasr AM, Moftah F, Abourehab MAS, Gad S. Design Formulation and Characterization of Valsartan Nanoethosomes for improving bioavailability. *Pharmaceutics*, 14, 11, 2022, 2268.

Patel, R., et al. Ethosomes: A promising tool for transdermal delivery of drug. *Pharmaceutical Development and Technology*, 18, 6, 2023, pp. 1247-1254.

Shelke O, Kulkarni A. Formulation, Development and Evaluation of Nano Ethosomal Gel of Tramadol Hydrochloride. *Journal of Nanomedicine and Nanotechnology*, 9, 5, 2018, 1000514

Singh, S., et al. Ethosomal drug delivery system: a novel approach for topical delivery of drugs. *Journal of Controlled Release*, 15, 2, 2023, 234-245.

Uner B, Ozdemir S, Pilevne SN, Celebi ARC.Timolol-loaded ethosomes for ophthalmic delivery: Reduction of high intraocular pressure in vivo. *International Journal of Pharmaceutics*, 640, 2023, 123021.

Verma P, Yadav AK, Gupta D, Nooreen Z. Review on ethosomes: A novel drug delivery system. *European Journal of Pharmaceutical and Medical Research*, 2023, 10, 2, 147-159